(Q34636927)

3 August 2017

1 reference

title

Haemophilia 2002: emerging risks of treatment (English)

1 reference

3 August 2017

0 references

Evatt BL

1

1 reference

3 August 2017

Farrugia A

series ordinal

2

1 reference

3 August 2017

Shapiro AD

series ordinal

3

1 reference

3 August 2017

Wilde JT

series ordinal

4

1 reference

3 August 2017

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

221-229

1 reference

Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

A new variant of Creutzfeldt-Jakob disease in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Transmission of BSE by blood transfusion in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Species-barrier-independent prion replication in apparently resistant species

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Prion protein and developments in its detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Eight prion strains have PrP(Sc) molecules with different conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

The use of implantable venous access devices (IVADs) in children with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Contrast venography in young haemophiliacs with implantable central venous access devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Port-A-Cath usage in children with haemophilia: experience of 53 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Central venous catheter infection in haemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

A prospective clinical trial of implantable central venous access in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Implantable venous access devices in children with hemophilia: a report of low infection rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Does protease inhibitor treatment induce increased bleeding tendency in haemophilia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Protease inhibitors and unusual bleeding in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Successful use of protease inhibitors in HIV-infected haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00612.X

10.1046/J.1365-2516.2002.00612.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference